PPARγ as a therapeutic target in central nervous system diseases

Neurochemistry International

Volumn 49, Issue 2, 2006, Pages 136-144

  Sundararajan, Sophia ^a   Jiang, Qingguang ^a   Heneka, Michael ^b   Landreth, Gary ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Alzheimer's disease; Amytrophic lateral sclerosis; Multiple sclerosis; Parkinson's disease; Stroke

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 2 [1 CARBOXY 2 [4 [2 (5 METHYL 2 PHENYL 4 OXAZOLYL)ETHOXY]PHENYL] ETHYLAMINO]BENZOIC ACID METHYL ESTER; 2 [1 CARBOXY 2 [4 [2 (5 METHYL 2 PHENYL 4 OXAZOLYL)ETHOXY]PHENYL]ETHYLAMINO]BENZOIC ACID METHYL ESTER; 2,4 THIAZOLIDINEDIONE DERIVATIVE; CELL NUCLEUS RECEPTOR; DOCOSAHEXAENOIC ACID; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; AUTACOID; NEUROPROTECTIVE AGENT;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; GENE EXPRESSION; HUMAN; INSULIN SENSITIVITY; MULTIPLE SCLEROSIS; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; RISK REDUCTION; STROKE; ANIMAL; BRAIN; BRAIN DISEASE; DISEASE MODEL; DRUG ANTAGONISM; DRUG POTENTIATION; ENCEPHALITIS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; PATHOPHYSIOLOGY; REVIEW; TRANSACTIVATION;

ANIMALIA;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BRAIN; BRAIN DISEASES; DISEASE MODELS, ANIMAL; ENCEPHALITIS; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION MEDIATORS; NEUROPROTECTIVE AGENTS; PPAR GAMMA; TRANS-ACTIVATION (GENETICS);

EID: 33744994576     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2006.03.020     Document Type: Article

References (85)

1. Aoun P., Simpkins J., et al. Role of PPAR-gamma ligands in neuroprotection against glutamate-induced cytotoxicity in retinal ganglion cells. Invest. Ophthalmol. Vis. Sci. 44 (2003) 2999-3004
2. Aranda A., and Pascual A. Nuclear hormone receptors and gene expression. Physiol. Rev. 81 (2001) 1269-1304
3. Barone F.C., and Feuerstein G.Z. Inflammatory mediators and stroke: new opportunities for novel therapeutics. J. Cereb. Blood Flow Metab. 19 (1999) 819-834
4. Barone F.C., Hillegass L.M., et al. Time-related changes in myeloperoxidase activity and leukotriene B4 receptor binding reflect leukocyte influx in cerebral focal stroke. Mol. Chem. Neuropathol. 24 (1995) 13-30
5. Becker K.J. Inflammation and acute stroke. Curr. Opin. Neurol. 11 (1998) 45-49
6. Berger J., and Moller D.E. The mechanisms of action of PPARs. Annu. Rev. Med. 53 (2002) 409-435
7. Breidert T., Callebert J., et al. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J. Neurochem. 82 (2002) 615-624
8. Camacho I.E., Serneels L., et al. Peroxisome proliferator-activated receptor gamma induces a clearance mechanism for the amyloid-beta peptide. J. Neurosci. 24 (2004) 10908-10917
9. Castrillo A., Diaz-Guerra M.J., et al. Inhibition of IkappaB kinase and IkappaB phosphorylation by 15-deoxy-Delta(12,14)-prostaglandin J(2) in activated murine macrophages. Mol. Cell. Biol. 20 (2000) 1692-1698
10. Castrillo A., and Tontonoz P. Nuclear receptors in macrophage biology: at the crossroads of lipid metabolism and inflammation. Annu. Rev. Cell Dev. Biol. 20 (2004) 455-480
11. Chopp M., Li Y., et al. Antibodies against adhesion molecules reduce apoptosis after transient middle cerebral artery occlusion in rat brain. J. Cereb. Blood Flow Metab. 16 (1996) 578-584
12. Cimini A., Benedetti E., et al. Expression of peroxisome proliferator-activated receptors (PPARs) and retinoic acid receptors (RXRs) in rat cortical neurons. Neuroscience 130 (2005) 325-337
13. Combs C.K., Johnson D.E., et al. Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J. Neurosci. 20 (2000) 558-567
14. Costello D.A., O'Leary D.M., et al. Agonists of peroxisome proliferator-activated receptor-gamma attenuate the Abeta-mediated impairment of LTP in the hippocampus in vitro. Neuropharmacology 49 (2005) 359-366
15. d'Abramo C., Massone S., et al. Role of peroxisome proliferator-activated receptor gamma in amyloid precursor protein processing and amyloid beta-mediated cell death. Biochem. J. 391 (2005) 693-698
16. Daynes R.A., and Jones D.C. Emerging roles of PPARs in inflammation and immunity. Nat. Rev. Immunol. 2 (2002) 748-759
17. Dehmer T., Heneka M., et al. Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J. Neurochem. 88 (2004) 494-501
18. Diab A., Deng C., et al. Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Delta(12, 14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis. J. Immunol. 168 (2002) 2508-2515
19. Diab A., Hussain R., et al. Ligands for the peroxisome proliferator-activated receptor-gamma and the retinoid X receptor exert additive anti-inflammatory effects on experimental autoimmune encephalomyelitis. J. Neuroimmunol. 148 (2004) 116-126
20. Diep Q., El Mabrouk M., et al. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma. Circulation 105 (2002) 2296-2302
21. Dobrian A.D., Schriver S.D., et al. Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity. Hypertension 43 (2004) 48-56
22. Dormandy J.A., Charbonnel B., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
23. Emerson M., and LeVine S. Experimental allergic encephalomyelitis is exacerbated in mice deficient for 12/15-lipoxygenase or 5-lipoxygenase. Brain Res. 1021 (2004) 140-145
24. Feinstein D. Therapeutic potential of peroxisome proliferator-activated receptor agonists for neurological disease. Diab. Tech. Ther. 5 (2003) 67-73
25. Feinstein D., Galea E., et al. Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis. Ann. Neurol. 51 (2002) 694-702
26. Feinstein D., Spagnolo A., et al. Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key?. Biochem. Pharm. 70 (2005) 177-188
27. Fuenzalida K., Aguilera M., et al. Peroxisome proliferator-activated receptor gamma is a novel target of the nerve growth factor signaling pathway in PC12 cells. J. Biol. Chem. 280 (2005) 9604-9609
28. Garcia-Bueno B., Madrigal J., et al. Peroxisome proliferator-activated receptor gamma activation decreases neuroinflammation in brain after stress in rats. Biol. Psych. 57 (2005) 885-894
29. Glass C.K., and Rosenfeld M.G. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev. 14 (2000) 121-141
30. Heneka M., Sastre M., et al. Acute treatment with the PPARγ agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain 128 (2005) 1442-1453
31. Heneka M.T., Feinstein D.L., et al. Peroxisome proliferator-activated receptor gamma agonists protect cerebellar granule cells from cytokine-induced apoptotic cell death by inhibition of inducible nitric oxide synthase. J. Neuroimmunol. 100 (1999) 156-168
32. Heneka M.T., Klockgether T., et al. Peroxisome proliferator-activated receptor-gamma ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo. J. Neurosci. 20 (2000) 6862-6867
33. Hirsch E., Breidert T., et al. The role of glial reaction and inflammation in Parkinson's disease. Ann. NY Acad. Sci. 991 (2003) 214-228
34. Hsueh W.A., and Law R. The central role of fat and effect of peroxisome proliferator-activated receptor-gamma on progression of insulin resistance and cardiovascular disease. Am. J. Cardiol. 92 (2003) 3J-9J
35. Iadecola C., and Ross M.E. Molecular pathology of cerebral ischemia: delayed gene expression and strategies for neuroprotection. Ann. NY Acad. Sci. 835 (1997) 203-217
36. Inestrosa N., Godoy J., et al. Peroxisome proliferator-activated receptor gamma is expressed in hippocampal neurons and its activation prevents beta-amyloid neurodegeneration: role of Wnt signaling. Exp. Cell Res. 304 (2005) 91-104
37. Jepsen K., Hermanson O., et al. Combinatorial roles of the nuclear receptor corepressor in transcription and development. Cell 102 (2000) 753-763
38. Jiang C., Ting A.T., et al. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391 (1998) 82-86
39. Kelly D., Campbell J.I., et al. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA. Nat. Immunol. 5 (2004) 104-112
40. Kiaei M., Kipiani K., et al. Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. Exp. Neurol. 191 (2005) 331-336
41. Kielian T., and Drew P.D. Effects of peroxisome proliferator-activated receptor-gamma agonists on central nervous system inflammation. J. Neurosci. Res. 71 (2003) 315-325
42. Kim E.J., Kwon K.J., et al. Effects of peroxisome proliferator-activated receptor agonists on LPS-induced neuronal death in mixed cortical neurons: associated with iNOS and COX-2. Brain Res. 941 (2002) 1-10
43. Kitamura Y., Shimohama S., et al. Increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-gamma in Alzheimer's disease brains. Biochem. Biophys. Res. Commun. 254 (1999) 582-586
44. Klotz L., Sastre M., et al. Noradrenaline induces expression of peroxisome proliferator activated receptor gamma (PPARgamma) in murine primary astrocytes and neurons. J. Neurochem. 86 (2003) 907-916
45. Klotz L., Schmidt M., et al. Proinflammatory stimulation and pioglitazone treatment regulate peroxisome proliferator-activated receptor {gamma} levels in peripheral blood mononuclear cells from healthy controls and multiple sclerosis patients. J. Immunol. 175 (2005) 4948-4955
46. Landreth G., and Heneka M. Peroxisome proliferator-activated receptor gamma agonists: potential therapeutic agents for neuroinflammation. Neuroinflammation: Mechanisms and Management (2002), P. Wood, Humana Press
47. Lehmann J.M., Lenhard J.M., et al. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem. 272 (1997) 3406-3410
48. Lim G.P., Yang F., et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J. Neurosci. 20 (2000) 5709-5714
49. Lim G.P., Yang F., et al. Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol. Aging 22 (2001) 983-991
50. Luna-Medina R., Cortes-Canteli M., et al. Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor gamma activation. J. Biol. Chem. 280 (2005) 21453-21462
51. Maeshiba Y., Kiyota Y., et al. Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys. Arzneimittelforschung 47 (1997) 29-35
52. McKay L.I., and Cidlowski J.A. Molecular control of immune/inflammatory responses: interactions between nuclear factor-kappa B and steroid receptor-signaling pathways. Endocr. Rev. 20 (1999) 435-459
53. McKenna N.J., and O'Malley B.W. Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 108 (2002) 465-474
54. Natarajan C., Muthian G., et al. Peroxisome proliferator-activated receptor-gamma-deficient heterozygous mice develop an exacerbated neural antigen-induced Th1 response and experimental allergic encephalomyelitis. J. Immunol. 171 (2003) 5743-5750
55. Negishi M., and Katoh H. Cyclopentenone prostaglandin receptors. Prostagl. Lipid Mediat. 68/69 (2002) 611-617
56. Niino M., Iwabuchi K., et al. Amelioration of experimental autoimmune encephalomyelitis in C57BL/6 mice by an agonist of peroxisome proliferator-activated receptor-gamma. J. Neuroimmunol. 116 (2001) 40-48
57. Pedersen, W., McMillan, P., et al., in press. Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp. Neurol.
58. Pedersen W.A., and Flynn E.R. Insulin resistance contributes to aberrant stress responses in the Tg2576 mouse model of Alzheimer's disease. Neurobiol. Dis. 17 (2004) 500-506
59. Pereira M.P., Hurtado O., et al. The nonthiazolidinedione PPARgamma agonist L-796 449 is neuroprotective in experimental stroke. J. Neuropathol. Exp. Neurol. 64 (2005) 797-805
60. Pershadsingh H., Heneka M., et al. Effect of pioglitazone treatment in a patient with secondary multiple sclerosis. J. Neuroinflammation 1 (2004) 3
61. Raikwar H., Muthian G., et al. PPARgamma antagonists exacerbate neural antigen-specific Th1 response and experimental allergic encephalomyelitis. J. Neuroimmunol. 167 (2005) 99-107
62. Relton J.K., and Rothwell N.J. Interleukin-1 receptor antagonist inhibits ischaemic and excitotoxic neuronal damage in the rat. Brain Res. Bull. 29 (1992) 243-246
63. Ricote M., Li A.C., et al. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391 (1998) 79-82
64. Risner, M.E., Saunders, A.M., et al., 2006. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenom. J.
65. Rossi A., Kapahi P., et al. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. Nature 403 (2000) 103-108
66. Ryan M.J., Didion S.P., et al. PPAR(gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice. Hypertension 43 (2004) 661-666
67. Sastre M., Dewachter I., et al. Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J. Neurosci. 23 (2003) 9796-9804
68. Sastre M., Dewachter I., et al. Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 443-448
69. Schmidt S., Moric E., et al. Anti-inflammatory and antiproliferative actions of PPAR-gamma agonists on T lymphocytes derived from MS patients. J. Leuk. Biol. 75 (2004) 478-485
70. Schutz B., Reimann J., et al. The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. J. Neurosci. 25 (2005) 7805-7812
71. Shimazu T., Inoue I., et al. A peroxisome proliferator-activated receptor-gamma agonist reduces infarct size in transient but not in permanent ischemia. Stroke 36 (2005) 353-359
72. Storer P., Xu J., et al. Peroxisome proliferator-activated receptor-gamma agonists inhibit the activation of microglia and astrocytes: implications for multiple sclerosis. J. Neuroimmunol. 161 (2005) 113-122
73. Sundararajan S., Gamboa J., et al. Peroxisome proliferator-activated receptor-gamma ligands reduce inflammation and infarction size in transient focal ischemia. Neuroscience 130 (2005) 685-696
74. Uryu S., Harada J., et al. Troglitazone inhibits both post-glutamate neurotoxicity and low-potassium-induced apoptosis in cerebellar granule neurons. Brain Res. 924 (2002) 229-236
75. Watson G.S., Cholerton B.A., et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am. J. Geriatr. Psychiatry 13 (2005) 950-958
76. Wayman N.S., Hattori Y., et al. Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. FASEB J. 16 (2002) 1027-1040
77. Weggen S., Eriksen J.L., et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414 (2001) 212-216
78. Willson T., Lambert M., et al. Peroxisome proliferator-activated receptor gamma and metabolic disease. Ann. Rev. Biochem. 70 (2001) 341-367
79. Yan Q., Radeke M.J., et al. Immunocytochemical localization of TrkB in the central nervous system of the adult rat. J. Comp. Neurol. 378 (1997) 135-157
80. Yan Q., Zhang J., et al. Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J. Neurosci. 23 (2003) 7504-7509
81. Yang G.Y., Gong C., et al. Inhibition of TNFalpha attenuates infarct volume and ICAM-1 expression in ischemic mouse brain. Neuroreport 9 (1998) 2131-2134
82. Yue T.L., Chen J., et al. In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation 104 (2001) 2588-2594
83. Zhang R.L., Chopp M., et al. Anti-ICAM-1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in the rat. Neurology 44 (1994) 1747-1751
84. Zhao, X., Ou, Z., et al., 2006. Peroxisome-proliferator-activated receptor-gamma (PPARgamma) activation protects neurons from NMDA excitotoxicity. Brain Res.
85. Zheng Z., and Yenari M.A. Post-ischemic inflammation: molecular mechanisms and therapeutic implications. Neurol. Res. 26 (2004) 884-892